XIDX
PYFA
Market cap371mUSD
Nov 12, Last price
550.00IDR
Name
Pyridam Farma Tbk PT
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, antibiotics, vitamins, supplements, and traditional herbal care products in Indonesia. The company operates in two segments, Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. It offers medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR extraction kit and extractor machine, speciment bag, sterile container, and tube stopper. The company also provides skin care products comprising Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel; products in the areas of alimentary t. and metabolism, blood and blood forming organs, cardiovascular system, dermatologicals, G.U. system and sex hormones, systemic corticosteroids, systemic antibacterial, sensory organs, as well as musculo-skeletal, nervous, and respiratory systems; and supplements and other preventive consumer health products with energy drinks and healthy ready-to-drink products. In addition, it engages in the research and development on biotechnology, life, and medical science. The company was founded in 1976 and is headquartered in Jakarta, Indonesia.
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||